Isoflurane anesthesia induces biphasic effect on dopamine release in the rat striatum. 2005

Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
Medical Clinic of Hamamatsu Base, Japan Air Self Defense Force, Hamamatsu City, Shizuoka 432-8551, Japan. yuadachi@poppy.ocn.ne.jp

The effect of isoflurane anesthesia on changes in the extracellular concentrations of dopamine (DA) and its metabolites (3-methoxytyramine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)) modulated by pargyline, monoamine oxidase inhibitor, was studied using in vivo microdialysis techniques. A microdialysis probe was implanted into the right striatum of male SD rats. Each rat (n=5-6) was given saline or the same volume of 30 or 75 mg kg(-1) pargyline intraperitoneally with or without 1 h isoflurane anesthesia (1 or 3%). Isoflurane anesthesia increased the extracellular concentration of DA in high dose (3%) and increased the metabolite concentrations in a dose-dependent manner. Pargyline administration increased the extracellular concentration of DA and 3-MT, and decreased that of other metabolites. After 30 mg kg(-1) pargyline treatment, 1% isoflurane-induced DA release and increasing of 3-MT were preserved, whereas high dose isoflurane (3%) decreased the concentration of metabolites (DOPAC and HVA), despite of the increase by low dose isoflurane (DOPAC). When 75 mg kg(-1) pargyline was administered, isoflurane anesthesia decreased the concentration of DA and DOPAC. The isoflurane-induced 3-MT increase was preserved in all experiments. Our results suggest that isoflurane anesthesia induced biphasic effect on DA regulation probably by the potentiation of DA release and the inhibition of DA synthesis. Isoflurane might modulate DA homeostasis presynaptically.

UI MeSH Term Description Entries
D007530 Isoflurane A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
D008297 Male Males
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010293 Pargyline A monoamine oxidase inhibitor with antihypertensive properties. Pargyline Hydrochloride,Hydrochloride, Pargyline
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005110 Extracellular Space Interstitial space between cells, occupied by INTERSTITIAL FLUID as well as amorphous and fibrous substances. For organisms with a CELL WALL, the extracellular space includes everything outside of the CELL MEMBRANE including the PERIPLASM and the cell wall. Intercellular Space,Extracellular Spaces,Intercellular Spaces,Space, Extracellular,Space, Intercellular,Spaces, Extracellular,Spaces, Intercellular
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
April 2006, Masui. The Japanese journal of anesthesiology,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
April 1996, Neurochemistry international,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
November 1992, Journal of neurochemistry,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
January 1985, Regulatory peptides. Supplement,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
October 1998, Neuroscience,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
January 1986, Psychopharmacology,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
December 2012, Brain research bulletin,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
January 1975, European journal of pharmacology,
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
May 2000, Synapse (New York, N.Y.),
Yushi U Adachi, and Shigeyuki Yamada, and Maiko Satomoto, and Hideyuki Higuchi, and Kazuhiko Watanabe, and Tomiei Kazama
January 1982, Acta biologica et medica Germanica,
Copied contents to your clipboard!